A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Atopic Dermatitis (AD)
Trial Locations (1)

200040

Huashan Hospital affiliated to Fudan University /ID# 268259, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY

NCT06503536 - A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review | Biotech Hunter | Biotech Hunter